Richard D Holly

This inventor holds 34 USPTO granted patents and 15 published patent applications and 3 EPO patents, primarily in Cytokine Research. Top assignees: Zymogenetics, Inc., University of Washington. Active years: 1994-2013.

USPTO Granted Patents = 34 (Patent Applications = 15)

% Patents Active = 55.9

EPO Patents = 3 (Patent Applications = 7)

Average Co-Inventor Count = 4.6

ph-index = 9

Forward Citations = 386(Granted Patents)

Company Filing History:

University of Washington

patents

where one patent can have more than one assignee

Years Active: 1994-2013

Loading Chart...

Areas of Expertise:

Cytokine

ZALPHA11 Ligand

Antibodies

Soluble Receptors

Polynucleotides

Fusion Proteins

Granulocyte

Macrophage

Hybrid Protein C

Thrombopoietin

Thrombin

Hematopoietic Cells

34 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8383775 - Cytokine zalpha11 ligand (2013-02-26),

2. 8227575 - Cytokine zalpha11 ligand antibodies (2012-07-24),

3. 8110180 - Method of use of cytokine ZALPHA11 ligand (2012-02-07),

4. 8017343 - Cytokine zalpha11 ligand antibodies and methods of use (2011-09-13),

5. 7998468 - Cytokine zalpha11 ligand antibodies (2011-08-16),

6. 7829075 - Method for expanding hematopoietic cells using cytokine zalpha11 ligand (2010-11-09),

7. 7763713 - Zalpha11 cytokine receptors (2010-07-27),

8. RE41129 - Cytokine zalpha11 ligand polynucleotides (2010-02-15),

9. 7629452 - Polynucleotides encoding soluble zalpha11 cytokine receptors (2009-12-08),

10. 7626002 - Cytokine zalpha11 ligand antibodies (2009-12-01),

11. 7611699 - Methods of using cytokine zalpha11 ligand (2009-11-03),

12. 7592425 - Cytokine zalpha11 ligand fusion proteins (2009-09-22),

13. 7579441 - Cytokine zalpha11 ligand fusion proteins (2009-08-25),

14. 7572892 - Cytokine zalpha11 ligand fusion proteins (2009-08-11),

15. 7569670 - Cytokine zalpha11 ligand fusion proteins (2009-08-04),

Title: Richard D. Holly - Innovator in Antibody Research

Introduction

Richard D. Holly is a distinguished inventor based in Seattle, Washington, with an impressive portfolio of 34 patents. His work primarily focuses on the development of antibodies that engage with cytokine zalpha11 ligand, contributing significantly to advancements in therapeutic applications and biotechnology.

Latest Patents

Among his latest contributions are patents related to antibodies that bind to polypeptides and peptides comprising the sequence of zalpha11 ligand, specifically detailed in SEQ ID NO: 2. These antibodies can target either the full-length sequence of 162 amino acid residues or various fragments, including a mature polypeptide of 131 amino acid residues and smaller peptide sequences. The range of antibodies includes polyclonal, monoclonal, murine, humanized, and neutralizing variants. In addition, methods for producing these antibodies are described, showcasing his innovative approach to biopharmaceutical development.

Career Highlights

Richard D. Holly has had a noteworthy career, having worked with prominent organizations such as Zymogenetics, Inc. and the University of Washington. His roles in these institutions have catalyzed groundbreaking research and advancements in the field of immunology, particularly in the creation of therapeutic antibodies.

Collaborations

Throughout his career, Richard has collaborated with esteemed colleagues, including Donald C. Foster and Julia E. Novak. These partnerships have fostered a collaborative environment that enhances research outcomes and accelerates innovation in antibody development.

Conclusion

In conclusion, Richard D. Holly's contributions to antibody research, particularly in relation to cytokine zalpha11 ligand, highlight his role as a leading innovator in biotechnology. With numerous patents to his name and a track record of collaboration with key figures in the industry, his work continues to influence the future of therapeutics and antibody applications.